Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone
Identifieur interne : 004198 ( Pmc/Corpus ); précédent : 004197; suivant : 004199Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone
Auteurs : Wen-Yen Chiou ; Chien-An Chen ; Moon-Sing Lee ; Hon-Yi Lin ; Chung-Yi Li ; Yu-Chieh Su ; Shiang-Jiun Tsai ; Shih-Kai HungSource :
- Medicine [ 0025-7974 ] ; 2016.
Abstract
As the number of long-term cervical cancer survivors continues to increase because of improvements in treatment, concerns about second primary malignancy have grown. The high-risk area of second primary cancers in cervical cancer survivors is the pelvis. Pelvic inflammatory disease (PID) could be a useful marker for gynecological cancers. Thus, we designed a large-scale, nationwide, controlled cohort study to investigate whether PID or other risk factors increased the risk of second primary cancers in patients with cervical cancer treated by surgery alone.
Between 2000 and 2010, a total of 24,444 cervical cancer patients were identified using the Registry Data for Catastrophic Illness and the National Health Insurance Research Database (NHIRD) of Taiwan. Patients who received definite surgery were selected. To exclude the effect on second primary malignancy by treatment modalities, all cervical patients who ever having received adjuvant or definite radiotherapy or chemotherapy for primary cervical cancer were excluded. Finally, 3860 cervical cancer patients treated by surgery alone without adjuvant treatments were analyzed.
Cox proportional hazards model was used for multivariate analysis and the Kaplan–Meier method was used to assess the cumulative risks. Regarding the incidence of second primary cancers, the standardized incidence ratio (SIR) was used.
The median follow-up time was 56.6 months. The 6-year cumulative risk of second primary cancers is 0.16% and 0.12% for PID and without PID, respectively. After adjustment for confounders, age of less than 50 years, the presence of diabetes mellitus, and PID were significantly positivity associated with the risk of second primary cancers. The hazard ratios (HRs) of age less than 50 years, diabetes mellitus, and PID were 1.38 (95% CI = 1.11–2.04), 1.40 (95% CI = 1.06–1.85), and 1.35 (95% CI = 1.00–1.81), respectively. A higher incidence of second primary cancers was observed in the genitals, bladder, and colon.
In conclusion, the incidence of second primary cancers was higher in the genitals, bladder, and colon in patients with cervical cancer treated with surgery alone. The patients with PID had a higher risk of second primary cancers.
Url:
DOI: 10.1097/MD.0000000000005409
PubMed: 27893679
PubMed Central: 5134872
Links to Exploration step
PMC:5134872Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone</title><author><name sortKey="Chiou, Wen Yen" sort="Chiou, Wen Yen" uniqKey="Chiou W" first="Wen-Yen" last="Chiou">Wen-Yen Chiou</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Public Health, College of Medicine, National Cheng Kung University, Tainan</nlm:aff></affiliation></author><author><name sortKey="Chen, Chien An" sort="Chen, Chien An" uniqKey="Chen C" first="Chien-An" last="Chen">Chien-An Chen</name><affiliation><nlm:aff id="aff4">Department of Radiation Oncology, Zhongxing Branch, Taipei City Hospital, Taipei</nlm:aff></affiliation></author><author><name sortKey="Lee, Moon Sing" sort="Lee, Moon Sing" uniqKey="Lee M" first="Moon-Sing" last="Lee">Moon-Sing Lee</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author><author><name sortKey="Lin, Hon Yi" sort="Lin, Hon Yi" uniqKey="Lin H" first="Hon-Yi" last="Lin">Hon-Yi Lin</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author><author><name sortKey="Li, Chung Yi" sort="Li, Chung Yi" uniqKey="Li C" first="Chung-Yi" last="Li">Chung-Yi Li</name><affiliation><nlm:aff id="aff3">Department of Public Health, College of Medicine, National Cheng Kung University, Tainan</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Department of Public Health, China Medical University, Taichung</nlm:aff></affiliation></author><author><name sortKey="Su, Yu Chieh" sort="Su, Yu Chieh" uniqKey="Su Y" first="Yu-Chieh" last="Su">Yu-Chieh Su</name><affiliation><nlm:aff id="aff6">Division of Hematology and Oncology, E-Da Hospital, Kaohsiung</nlm:aff></affiliation><affiliation><nlm:aff id="aff7">School of Medicine, I-Shou University, Kaohsiung, Taiwan.</nlm:aff></affiliation></author><author><name sortKey="Tsai, Shiang Jiun" sort="Tsai, Shiang Jiun" uniqKey="Tsai S" first="Shiang-Jiun" last="Tsai">Shiang-Jiun Tsai</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation></author><author><name sortKey="Hung, Shih Kai" sort="Hung, Shih Kai" uniqKey="Hung S" first="Shih-Kai" last="Hung">Shih-Kai Hung</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">27893679</idno><idno type="pmc">5134872</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134872</idno><idno type="RBID">PMC:5134872</idno><idno type="doi">10.1097/MD.0000000000005409</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">004198</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004198</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone</title><author><name sortKey="Chiou, Wen Yen" sort="Chiou, Wen Yen" uniqKey="Chiou W" first="Wen-Yen" last="Chiou">Wen-Yen Chiou</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation><affiliation><nlm:aff id="aff3">Department of Public Health, College of Medicine, National Cheng Kung University, Tainan</nlm:aff></affiliation></author><author><name sortKey="Chen, Chien An" sort="Chen, Chien An" uniqKey="Chen C" first="Chien-An" last="Chen">Chien-An Chen</name><affiliation><nlm:aff id="aff4">Department of Radiation Oncology, Zhongxing Branch, Taipei City Hospital, Taipei</nlm:aff></affiliation></author><author><name sortKey="Lee, Moon Sing" sort="Lee, Moon Sing" uniqKey="Lee M" first="Moon-Sing" last="Lee">Moon-Sing Lee</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author><author><name sortKey="Lin, Hon Yi" sort="Lin, Hon Yi" uniqKey="Lin H" first="Hon-Yi" last="Lin">Hon-Yi Lin</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author><author><name sortKey="Li, Chung Yi" sort="Li, Chung Yi" uniqKey="Li C" first="Chung-Yi" last="Li">Chung-Yi Li</name><affiliation><nlm:aff id="aff3">Department of Public Health, College of Medicine, National Cheng Kung University, Tainan</nlm:aff></affiliation><affiliation><nlm:aff id="aff5">Department of Public Health, China Medical University, Taichung</nlm:aff></affiliation></author><author><name sortKey="Su, Yu Chieh" sort="Su, Yu Chieh" uniqKey="Su Y" first="Yu-Chieh" last="Su">Yu-Chieh Su</name><affiliation><nlm:aff id="aff6">Division of Hematology and Oncology, E-Da Hospital, Kaohsiung</nlm:aff></affiliation><affiliation><nlm:aff id="aff7">School of Medicine, I-Shou University, Kaohsiung, Taiwan.</nlm:aff></affiliation></author><author><name sortKey="Tsai, Shiang Jiun" sort="Tsai, Shiang Jiun" uniqKey="Tsai S" first="Shiang-Jiun" last="Tsai">Shiang-Jiun Tsai</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation></author><author><name sortKey="Hung, Shih Kai" sort="Hung, Shih Kai" uniqKey="Hung S" first="Shih-Kai" last="Hung">Shih-Kai Hung</name><affiliation><nlm:aff id="aff1">Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</nlm:aff></affiliation><affiliation><nlm:aff id="aff2">School of Medicine, Tzu Chi University, Hualian</nlm:aff></affiliation></author></analytic><series><title level="j">Medicine</title><idno type="ISSN">0025-7974</idno><idno type="eISSN">1536-5964</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>As the number of long-term cervical cancer survivors continues to increase because of improvements in treatment, concerns about second primary malignancy have grown. The high-risk area of second primary cancers in cervical cancer survivors is the pelvis. Pelvic inflammatory disease (PID) could be a useful marker for gynecological cancers. Thus, we designed a large-scale, nationwide, controlled cohort study to investigate whether PID or other risk factors increased the risk of second primary cancers in patients with cervical cancer treated by surgery alone.</p><p>Between 2000 and 2010, a total of 24,444 cervical cancer patients were identified using the Registry Data for Catastrophic Illness and the National Health Insurance Research Database (NHIRD) of Taiwan. Patients who received definite surgery were selected. To exclude the effect on second primary malignancy by treatment modalities, all cervical patients who ever having received adjuvant or definite radiotherapy or chemotherapy for primary cervical cancer were excluded. Finally, 3860 cervical cancer patients treated by surgery alone without adjuvant treatments were analyzed.</p><p>Cox proportional hazards model was used for multivariate analysis and the Kaplan–Meier method was used to assess the cumulative risks. Regarding the incidence of second primary cancers, the standardized incidence ratio (SIR) was used.</p><p>The median follow-up time was 56.6 months. The 6-year cumulative risk of second primary cancers is 0.16% and 0.12% for PID and without PID, respectively. After adjustment for confounders, age of less than 50 years, the presence of diabetes mellitus, and PID were significantly positivity associated with the risk of second primary cancers. The hazard ratios (HRs) of age less than 50 years, diabetes mellitus, and PID were 1.38 (95% CI = 1.11–2.04), 1.40 (95% CI = 1.06–1.85), and 1.35 (95% CI = 1.00–1.81), respectively. A higher incidence of second primary cancers was observed in the genitals, bladder, and colon.</p><p>In conclusion, the incidence of second primary cancers was higher in the genitals, bladder, and colon in patients with cervical cancer treated with surgery alone. The patients with PID had a higher risk of second primary cancers.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Tsai, Sj" uniqKey="Tsai S">SJ Tsai</name></author><author><name sortKey="Huang, Ys" uniqKey="Huang Y">YS Huang</name></author><author><name sortKey="Tung, Ch" uniqKey="Tung C">CH Tung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chiang, Cj" uniqKey="Chiang C">CJ Chiang</name></author><author><name sortKey="Chen, Yc" uniqKey="Chen Y">YC Chen</name></author><author><name sortKey="Chen, Cj" uniqKey="Chen C">CJ Chen</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Lang, Hc" uniqKey="Lang H">HC Lang</name></author><author><name sortKey="Wu, Sl" uniqKey="Wu S">SL Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaturvedi, Ak" uniqKey="Chaturvedi A">AK Chaturvedi</name></author><author><name sortKey="Engels, Ea" uniqKey="Engels E">EA Engels</name></author><author><name sortKey="Gilbert, Es" uniqKey="Gilbert E">ES Gilbert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hemminki, K" uniqKey="Hemminki K">K Hemminki</name></author><author><name sortKey="Dong, C" uniqKey="Dong C">C Dong</name></author><author><name sortKey="Vaittinen, P" uniqKey="Vaittinen P">P Vaittinen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Teng, Cj" uniqKey="Teng C">CJ Teng</name></author><author><name sortKey="Huon, Lk" uniqKey="Huon L">LK Huon</name></author><author><name sortKey="Hu, Yw" uniqKey="Hu Y">YW Hu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwab, M" uniqKey="Schwab M">M Schwab</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Hw" uniqKey="Lin H">HW Lin</name></author><author><name sortKey="Tu, Yy" uniqKey="Tu Y">YY Tu</name></author><author><name sortKey="Lin, Sy" uniqKey="Lin S">SY Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Hf" uniqKey="Chen H">HF Chen</name></author><author><name sortKey="Chen, P" uniqKey="Chen P">P Chen</name></author><author><name sortKey="Li, Cy" uniqKey="Li C">CY Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Levi, F" uniqKey="Levi F">F Levi</name></author><author><name sortKey="Te, Vc" uniqKey="Te V">VC Te</name></author><author><name sortKey="Randimbison, L" uniqKey="Randimbison L">L Randimbison</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kleinerman, Ra" uniqKey="Kleinerman R">RA Kleinerman</name></author><author><name sortKey="Boice, Jd" uniqKey="Boice J">JD Boice</name></author><author><name sortKey="Storm, Hh" uniqKey="Storm H">HH Storm</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Purdie, Dm" uniqKey="Purdie D">DM Purdie</name></author><author><name sortKey="Bain, Cj" uniqKey="Bain C">CJ Bain</name></author><author><name sortKey="Siskind, V" uniqKey="Siskind V">V Siskind</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chiaffarino, F" uniqKey="Chiaffarino F">F Chiaffarino</name></author><author><name sortKey="Pelucchi, C" uniqKey="Pelucchi C">C Pelucchi</name></author><author><name sortKey="Negri, E" uniqKey="Negri E">E Negri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Risch, Ha" uniqKey="Risch H">HA Risch</name></author><author><name sortKey="Howe, Gr" uniqKey="Howe G">GR Howe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parazzini, F" uniqKey="Parazzini F">F Parazzini</name></author><author><name sortKey="La Vecchia, C" uniqKey="La Vecchia C">C La Vecchia</name></author><author><name sortKey="Negri, E" uniqKey="Negri E">E Negri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Von Hertzen, Lc" uniqKey="Von Hertzen L">LC von Hertzen</name></author><author><name sortKey="Joensuu, H" uniqKey="Joensuu H">H Joensuu</name></author><author><name sortKey="Haahtela, T" uniqKey="Haahtela T">T Haahtela</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vinchant, M" uniqKey="Vinchant M">M Vinchant</name></author><author><name sortKey="Poncelet, C" uniqKey="Poncelet C">C Poncelet</name></author><author><name sortKey="Ziol, M" uniqKey="Ziol M">M Ziol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manavi, K" uniqKey="Manavi K">K Manavi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tokajuk, A" uniqKey="Tokajuk A">A Tokajuk</name></author><author><name sortKey="Krzyzanowska Grycel, E" uniqKey="Krzyzanowska Grycel E">E Krzyzanowska-Grycel</name></author><author><name sortKey="Tokajuk, A" uniqKey="Tokajuk A">A Tokajuk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giovannucci, E" uniqKey="Giovannucci E">E Giovannucci</name></author><author><name sortKey="Harlan, Dm" uniqKey="Harlan D">DM Harlan</name></author><author><name sortKey="Archer, Mc" uniqKey="Archer M">MC Archer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gallagher, Ej" uniqKey="Gallagher E">EJ Gallagher</name></author><author><name sortKey="Leroith, D" uniqKey="Leroith D">D LeRoith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diamond, Mp" uniqKey="Diamond M">MP Diamond</name></author><author><name sortKey="Entman, Ss" uniqKey="Entman S">SS Entman</name></author><author><name sortKey="Salyer, Sl" uniqKey="Salyer S">SL Salyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pandey, A" uniqKey="Pandey A">A Pandey</name></author><author><name sortKey="Forte, V" uniqKey="Forte V">V Forte</name></author><author><name sortKey="Abdallah, M" uniqKey="Abdallah M">M Abdallah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hammer, A" uniqKey="Hammer A">A Hammer</name></author><author><name sortKey="Rositch, A" uniqKey="Rositch A">A Rositch</name></author><author><name sortKey="Qeadan, F" uniqKey="Qeadan F">F Qeadan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tay, Sk" uniqKey="Tay S">SK Tay</name></author><author><name sortKey="Ngan, Hy" uniqKey="Ngan H">HY Ngan</name></author><author><name sortKey="Chu, Ty" uniqKey="Chu T">TY Chu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Crotty Alexander, Le" uniqKey="Crotty Alexander L">LE Crotty Alexander</name></author><author><name sortKey="Shin, S" uniqKey="Shin S">S Shin</name></author><author><name sortKey="Hwang, Jh" uniqKey="Hwang J">JH Hwang</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27893679</article-id><article-id pub-id-type="pmc">5134872</article-id><article-id pub-id-type="publisher-id">MD-D-16-02103</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000005409</article-id><article-id pub-id-type="art-access-id">05409</article-id><article-categories><subj-group subj-group-type="heading"><subject>3700</subject></subj-group><subj-group><subject>Research Article</subject><subject>Observational Study</subject></subj-group></article-categories><title-group><article-title>Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chiou</surname><given-names>Wen-Yen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Chien-An</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Moon-Sing</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hon-Yi</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chung-Yi</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff3"><sup>c</sup></xref><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Yu-Chieh</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff6"><sup>f</sup></xref><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Shiang-Jiun</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref rid="cor1" ref-type="corresp"><sup>∗</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hung</surname><given-names>Shih-Kai</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref rid="cor1" ref-type="corresp"><sup>∗</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Desapriya.</surname><given-names>Ediriweera</given-names></name></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi</aff><aff id="aff2"><label>b</label>School of Medicine, Tzu Chi University, Hualian</aff><aff id="aff3"><label>c</label>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan</aff><aff id="aff4"><label>d</label>Department of Radiation Oncology, Zhongxing Branch, Taipei City Hospital, Taipei</aff><aff id="aff5"><label>e</label>Department of Public Health, China Medical University, Taichung</aff><aff id="aff6"><label>f</label>Division of Hematology and Oncology, E-Da Hospital, Kaohsiung</aff><aff id="aff7"><label>g</label>School of Medicine, I-Shou University, Kaohsiung, Taiwan.</aff><author-notes id="cor1"><corresp><label>∗</label>Correspondence: Shiang-Jiun Tsai, Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Min-Sheng Road, Dalin Town, Chiayi 62247, Taiwan (e-mail: <email>oncology5672@yahoo.com.tw</email>); Shih-Kai Hung, Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Min-Sheng Road, Dalin Town, Chiayi 62247, Taiwan (e-mail: <email>oncology158@yahoo.com.tw</email>).</corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2016</year></pub-date><volume>95</volume><issue>47</issue><elocation-id>e5409</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>23</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-95-e5409.pdf"></self-uri><abstract><title>Abstract</title><p>As the number of long-term cervical cancer survivors continues to increase because of improvements in treatment, concerns about second primary malignancy have grown. The high-risk area of second primary cancers in cervical cancer survivors is the pelvis. Pelvic inflammatory disease (PID) could be a useful marker for gynecological cancers. Thus, we designed a large-scale, nationwide, controlled cohort study to investigate whether PID or other risk factors increased the risk of second primary cancers in patients with cervical cancer treated by surgery alone.</p><p>Between 2000 and 2010, a total of 24,444 cervical cancer patients were identified using the Registry Data for Catastrophic Illness and the National Health Insurance Research Database (NHIRD) of Taiwan. Patients who received definite surgery were selected. To exclude the effect on second primary malignancy by treatment modalities, all cervical patients who ever having received adjuvant or definite radiotherapy or chemotherapy for primary cervical cancer were excluded. Finally, 3860 cervical cancer patients treated by surgery alone without adjuvant treatments were analyzed.</p><p>Cox proportional hazards model was used for multivariate analysis and the Kaplan–Meier method was used to assess the cumulative risks. Regarding the incidence of second primary cancers, the standardized incidence ratio (SIR) was used.</p><p>The median follow-up time was 56.6 months. The 6-year cumulative risk of second primary cancers is 0.16% and 0.12% for PID and without PID, respectively. After adjustment for confounders, age of less than 50 years, the presence of diabetes mellitus, and PID were significantly positivity associated with the risk of second primary cancers. The hazard ratios (HRs) of age less than 50 years, diabetes mellitus, and PID were 1.38 (95% CI = 1.11–2.04), 1.40 (95% CI = 1.06–1.85), and 1.35 (95% CI = 1.00–1.81), respectively. A higher incidence of second primary cancers was observed in the genitals, bladder, and colon.</p><p>In conclusion, the incidence of second primary cancers was higher in the genitals, bladder, and colon in patients with cervical cancer treated with surgery alone. The patients with PID had a higher risk of second primary cancers.</p></abstract><kwd-group><title>Keywords</title><kwd>cervical cancer</kwd><kwd>pelvic inflammatory disease</kwd><kwd>second primary malignancy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Cervical cancer is the second most frequent cancer among women worldwide, and it remains an important and prevalent malignant disease in Taiwan.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> Although cervical cancer of females has declined in Taiwan since beginning in 1995 because National Health Insurance (NHI) has provided free mass screening of cervical neoplasia since 1995. The national Pap smear screening program significantly reduced cervical cancer risk explaining the dramatic decline in invasive cancer incidence after 1996.<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> Cervical cancer was still the 7th prevalent cancer in women in Taiwan in 2013.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> In 2006, there was an annual incidence rate of 16.2 per 100,000 people for invasive cervical cancer and a mortality rate of 7.8 per 100,000 people in Taiwan.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> A study ever showed that the average lifetime costs (10 years) for cervical cancer were NT$511,563 in Taiwan (in 2012 NTD, 1USD≠NTD 33).<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup></p><p>The 3 primary treatment modalities for this disease are surgery, radiotherapy, and chemotherapy. As treatment improves with the introduction of new agents and modern techniques, the number of long-term cervical cancer survivors continues to increase, in addition to concerns about second primary malignancies. Radiotherapy has a critical role in the primary management of patients with cervical cancer, and it has been reported that radiotherapy increases the risk of second cancers at sites in close proximity to the cervix.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> In addition to radiotherapy, chemotherapy, human papillomavirus (HPV) infection, and cigarette smoking elevate the risk for second primary cancers among cervical cancer survivors.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup> In an another nationwide population-based study in Taiwan, cervical cancer treatments, including both radiotherapy (HR = 1.27, 95% CI = 1.14–1.43) and chemotherapy (HR = 1.41, 95% CI = 1.25–1.59), were shown to increase secondary primary malignancy risk, but not surgery (HR = 0.94, 95% CI = 0.84–1.04).<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> For surgery, secondary primary cancer is not being considered as a substantial long-term clinical complication of cancer surgery, except in some breast, colon, and stomach cancer survivors, such as angiosarcoma in a lymphedema arm postaxillary lymph node dissection in breast cancers patients.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> Interestingly, the high-risk area for second primary cancers in cervical cancer survivors is the pelvis, even among patients who did not receive radiotherapy.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Recently, pelvic inflammatory disease (PID) was identified as a useful marker for gynecological cancers.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup></p><p>Thus, we designed a large-scale, nationwide, controlled cohort study to investigate whether PID and other risk factors increased the risk of second primary cancers in patients with cervical cancer treated with surgery alone without chemotherapy or radiotherapy.</p></sec><sec><label>2</label><title>Materials and methods</title><sec><label>2.1</label><title>Ethics statement</title><p>This study was approved by the Institutional Review Board of Buddhist Dalin Tzu Chi General Hospital, and the approval number is B10001017. The procedures were performed in accordance with the ethical standards of the committee on human experimentation of our institution and the Declaration of Helsinki. The institutional review board waived the need for written informed consent from the participants because the analyzed data consisted of anonymous secondary data released to the public for research.</p></sec><sec><label>2.2</label><title>Patients and study design</title><p>The study analyzed 2000 to 2010 data from the National Health Insurance Research Database (NHIRD), provided by the National Research Institutes in Taiwan. The NHIRD contains the medical benefit claims for 97% of the population from a registry of board-certified physicians and contracted medical facilities. The database contains comprehensive information on insured subjects, including the dates of clinical visits, diagnostic codes, details about prescriptions, and expenditure amounts.</p><p>Data on each patient were collected starting from the first hospitalization or outpatient visit in 2000. Patients were initially identified as having cervical cancer according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) code 180, from Registry Data for Catastrophic Illness. Catastrophic illness certificate, a peer-confirmed data subset, which could further ensure the accuracy of a cancer diagnosis was used for validation of cancer diagnosis.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup></p><p>We identified 24,444 patients who were newly diagnosed with cervical cancer confirmed by catastrophic illness certificates and between 2000 and 2010. Patients who received definite surgery were selected. To exclude the effect on second primary malignancy by treatment modalities, all cervical patients who ever having received adjuvant or definite radiotherapy or chemotherapy for primary cervical cancer were excluded (Fig. <xref ref-type="fig" rid="F1">1</xref>). Patients who underwent surgery before diagnosis, those who developed distant metastasis before surgery, were also excluded.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>A flowchart presenting the selection and group allocation of the cervical cancer patients cohort treated by surgery alone without adjuvant or definite radiotherapy or chemotherapy divided into pelvic inflammatory disease (PID) and non-PID groups.</p></caption><graphic xlink:href="medi-95-e5409-g001"></graphic></fig><p>Finally, 3860 cervical cancer patients treated by surgery alone without adjuvant treatments were analyzed. Figure <xref ref-type="fig" rid="F1">1</xref> shows the flow chart of patient selection. This cervical cancer cohort treated by surgery alone was divided into PID and non-PID groups.</p><p>The primary dependent variable was any secondary cancer (ICD-9-CM codes 140–165, 170–176, 179, 181–193, and 195–199). The adjusted independent variables included age, comorbidities, geographic region, urbanization level, and socioeconomic status. Comorbidities included hypertension (ICD-9-CM codes 401–405), diabetes mellitus (ICD-9-CM code 250), coronary heart disease (ICD-9-CM codes 410–414), hyperlipidemia (ICD-9-CM codes 2720–2724), PID (ICD-9-CM codes 614–616), and chronic obstructive pulmonary disease (ICD-9-CM codes 491, 492, and 496). For the purposes of the study, the country was divided into 4 geographic regions (Northern, Central, Southern, Eastern) and 3 urbanization levels (urban, suburban, rural). This study also used enrollee category (EC) as a proxy measure for socioeconomic status. All patients were categorized as EC1 (the highest socioeconomic status), EC2, EC3, EC4 (the lowest socioeconomic status), or other. The association of these variables with any second primary cancer was assessed.</p><p>Regarding the incidence of second primary cancers, the standardized incidence ratio (SIR) was used. In brief, we used the patients’ ages at diagnosis for stratification and counted the numbers of second primary cancers (Y1) and person-years (X) in different age groups. We then calculated standardized rate numbers of cases (Y2) for comparison with the 2000 global standard population (A). The predicted risks for second primary cancer were estimated using the equation Y2 = Y1 × A/X. According to this formula, we could obtain standardized rate numbers of cases for different cancers and years. Finally, we summed the number of cases (Yn). The health promotion administration announced the standardized rate per 100,000 people (Y0), and we could use these data as our reference. We could evaluate the SIR using the equation SIR = Yn/Y0 × 10<sup>5</sup>.</p></sec><sec><label>2.3</label><title>Statistical analysis</title><p>The statistical software packages SAS (version 9.2; SAS Institute, Inc., Cary, NC) and SPSS (version 17; SPSS, Inc., Chicago, IL) were used for data analysis. Pearson Chi-squared test was used to explore the differences between categorical variables in the different groups. The PID cumulative risk and survival rates were estimated using the Kaplan–Meier method and compared using the log-rank test. A Cox proportional hazard regression model was used to calculate the adjusted risk after adjusting for confounders. <italic>P</italic> < 0.05 was defined as statistically significant. The potential risk factors included age, comorbidities, geographic region, urbanization level, and socioeconomic status.</p></sec></sec><sec><label>3</label><title>Results</title><p>The 5-year overall survival rate for all cervical cancer patients treated by surgery alone without adjuvant or definite radiotherapy or chemotherapy was 94.7%. The median follow-up time was 56.6 months. The characteristics and comorbidities of the patients included in the study are shown in Table <xref ref-type="table" rid="T1">1</xref>. The SIR of second primary cancers is shown in Table <xref ref-type="table" rid="T2">2</xref>. Higher frequencies of second primary cancers were observed in the genitals, bladder, and colon. The SIRs for these sites were 5.52 (95% CI = 3.02–6.12), 1.58 (95% CI = 1.12–2.34), and 1.47 (95% CI = 1.16–2.18), respectively. Patients with PID had higher frequencies of second primary cancers (Fig. <xref ref-type="fig" rid="F2">2</xref>). The 6-year cumulative risk of second primary cancers is 0.16% and 0.12% for PID and without PID, respectively.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of cervical cancer patients treated by surgery alone without adjuvant or definite radiotherapy or chemotherapy.</p></caption><graphic xlink:href="medi-95-e5409-g002"></graphic></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Standardized incidence ratio (SIR) of various second primary cancers.</p></caption><graphic xlink:href="medi-95-e5409-g003"></graphic></table-wrap><fig id="F2" position="float"><label>Figure 2</label><caption><p>The risk of second primary cancers according to the presence or absence of pelvic inflammatory disease (PID).</p></caption><graphic xlink:href="medi-95-e5409-g004"></graphic></fig><p>After adjustment for age, comorbidities, urbanization level, geographic region, and EC, the hazard ratios (HRs) for age less than 50 years, the presence of diabetes mellitus, and PID were statistical significant (Table <xref ref-type="table" rid="T3">3</xref>). The HRs of age less than 50 years, diabetes mellitus, and PID were 1.38 (95% CI = 1.11–2.04), 1.40 (95% CI = 1.06–1.85), and 1.35 (95% CI = 1.00–1.81), respectively. Hypertension, coronary heart disease, hyperlipidemia, chronic obstructive pulmonary disease, urbanization level, geographic region, and EC were not statistical significant.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Crude and adjusted HRs for second primary cancers.</p></caption><graphic xlink:href="medi-95-e5409-g005"></graphic></table-wrap></sec><sec><label>4</label><title>Discussion</title><p>Based on our population-based study using NHIRD data, the risks for second primary cancers of the genitals, bladder, and colon in women with surgically removed colon cancer were significantly elevated. Several series reported similar findings. A study using data from the Swedish Family-Cancer Database identified elevated SIRs for cancers of the aerodigestive tract, anus, pancreas, lung, genitals, and urinary bladder in women with in situ or invasive cervical cancer.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> Kleinerman et al<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> also revealed that most second cancers arose in the rectum, vagina, vulva, ovaries, and bladder. Taken together, the area of greatest risk for second primary cancers in cervical cancer survivors is the pelvis.</p><p>Consistent with the presence of several established cancer risk factors among cervical cancer survivors, we identified age, diabetes mellitus, and PID as significant variables. In epidemiological findings, several studies reported low parity, nulliparity, and infertility as important risk factors for gynecological cancers and frequent complications of PID.<sup>[<xref rid="R14" ref-type="bibr">14</xref>–<xref rid="R16" ref-type="bibr">16</xref>]</sup> However, the conclusions of reported studies are inconsistent.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup> Recently, Lin et al<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> conducted a large-scale, nationwide, controlled cohort study and demonstrated that PID raised the risk of developing ovarian cancer. Specifically, multiple episodes of PID increased the risk of cancer in their study. Our study also found that patients with PID had higher rates of second primary cancers. After adjustment for confounding factors, PID remained a significant predictor. Chronic inflammation or infection could contribute to the development or activation of malignant disease.<sup>[<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]</sup> PID might constitute a marker for gynecological cancers that could enable early treatment and improved prognosis.</p><p>In this study, women aged 50 years or younger who had PID had a higher risk of developing secondary primary malignancies than older women. Risch and Howe<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> uncovered that the risk of second primary cancer was increased in women with PID who were 20 years or younger. Manavi<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> reported that women between 16 and 19 years of age had the highest prevalence of chlamydial infection, and a proportion of these women eventually developed PID. Lin et al<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> further demonstrated that the risk of ovarian cancer increased with increasing frequency of PID episodes. Although differences in outcomes between ethnic groups were noted, younger women with PID might be at higher risk of recurrent episodes of PID and therefore at greater risk of secondary primary malignancy.</p><p>Epidemiological data indicate that diabetes increases the risk of cancer.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> The frequencies of type 2 diabetes mellitus and malignant tumors are increasing continuously, and these diseases cause serious health problems.<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> Population-based epidemiologic studies revealed that the coexistence of type 2 diabetes and malignant tumors is more frequent than expected according to the age-corrected incidence. In experiments studies, metabolic changes associated with hyperinsulinemia played an important role in the relationship between cancer and type 2 diabetes mellitus.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> We also found that diabetes mellitus was an important factor influencing the risk of secondary primary malignancy. Importantly, women with diabetes were previously found to have an increased risk of PID.<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> Cancer is a complicated multistep process. Secondary primary malignancy presents a more complex situation. Recent studies illustrated that different treatment modalities, including various combinations of antidiabetic drugs, can modify cancer risk.<sup>[<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R25" ref-type="bibr">25</xref>]</sup> According to present knowledge, developing and utilizing optimal treatment modalities are suggested.</p><p>Our study had several limitations. First, the database does not contain information regarding the classification and severity of PID. However, the NHI covered approximately 97% of the island's population, and we could verify PID episodes. The trend identified in the study should not have been affected by the missing information. Second, almost all patients diagnosed as PID would receive treatments in Taiwan, because most residents in Taiwan are covered by NHI program and the treatment fee is free. Therefore, it could not differentiate whether no treatment of PID would further increase the risk of secondary malignancy in this study. Third, HPV is a cause of cervical cancer, vaginal cancer, vulva cancer and should be incorporated into this secondary malignancy study. However, there is no data about HPV vaccination in our NHIRD database because HPV vaccination is still self-paid, not covered by NHI and is therefore not included in NHIRD. However, HPV prevalence is relatively low in Asia compared to that in non-Asian areas (11–19% vs 57–75%).<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> The importance of HPV infection was likely reduced in our cohort. Fourth, tobacco use might be a risk factor for secondary primary cancers.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup> The database does not contain this information. However, tobacco use is correlated with chronic obstructive pulmonary disease. We used chronic obstructive pulmonary disease instead of tobacco use for adjustment. Taken together and given the robustness of both the evidence and statistical analyses used in this study, these limitations are unlikely to have compromised our results.</p><p>Cervical cancer treatment strategy could not be affected by our study findings because patients in our study all received surgery and all not received radiotherapy or chemotherapy. Cancer treatment response is still the first priority to be considered because of the high mortality and low incidence of second malignancy. However, PID should be treated or prevented in cervical cancer patients because our study showed PID is a risk factor of second malignancy even after adjustment of several possible contributing factors.</p><p>For survey of the possible second malignancy, healthcare provider or clinical physicians should pay more attention to cervical cancer patients who has risk factors, like young age, history of PID, diabetes mellitus, and especially to these sites, including female genital organs, bladder, and colon.</p><p>In conclusion, higher frequencies of second primary cancers were observed in the genitals, bladder, and colon in women with cervical cancer treated via surgery alone. Patients with PID had higher incidences of second primary cancers.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: EC = enrollee category, HPV = human papillomavirus, HR = hazard ratio, ICD-9-CM = International Classification of Disease, Ninth Revision, Clinical Modification, NHI = National Health Insurance, NHIRD = National Health Insurance Research Database, NTD = New Taiwan Dollar, PID = pelvic inflammatory disease, SIR = standardized incidence ratio, USD = United States Dollar.</p></fn><fn fn-type="financial-disclosure"><p>Funding: This study was partly based on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health in Taiwan and managed by National Health Research Institutes (registry number 100266). However, the interpretation and conclusions contained herein are not those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes.</p></fn><fn fn-type="equal"><p>W-YC and C-AC contributed equally to this work.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>YS</given-names></name><name><surname>Tung</surname><given-names>CH</given-names></name><etal></etal></person-group><article-title>Increased risk of ischemic stroke in cervical cancer patients: a nationwide population-based study</article-title>. <source>Radiat Oncol</source><year>2013</year>;<volume>8</volume>:<fpage>41</fpage>.<pub-id pub-id-type="pmid">23448602</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>Cancer trends in Taiwan</article-title>. <source>Jpn J Clin Oncol</source><year>2010</year>;<volume>40</volume>:<fpage>897</fpage>–<lpage>904</lpage>.<pub-id pub-id-type="pmid">20495192</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="book"><article-title>MOHW. The Ministry of Health and Welfare Announces the 2013 Cancer Incidence Data; Colorectal Cancer Continues to Be on Top</article-title>. <year>2016</year>; <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.mohw.gov.tw/EN/Ministry/DM2_P.aspx?f_list_no=378&fod_list_no=5760&doc_no=54431">http://www.mohw.gov.tw/EN/Ministry/DM2_P.aspx?f_list_no=378&fod_list_no=5760&doc_no=54431</ext-link></comment><date-in-citation>Accessed 10/03, 2016</date-in-citation>.</mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="book"><article-title>Taiwan Cancer Registry, Department of Health (Taiwan)</article-title>. <source>Cancer Incidence and Mortality Rates in Taiwan</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://crs.cph.ntu.edu.tw/uploadimages/Leading_10.pdf">http://crs.cph.ntu.edu.tw/uploadimages/Leading_10.pdf</ext-link></comment><year>2006</year><date-in-citation>Accessed 10/03, 2016</date-in-citation>.</mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>HC</given-names></name><name><surname>Wu</surname><given-names>SL</given-names></name></person-group><article-title>Lifetime costs of the top five cancers in Taiwan</article-title>. <source>Eur J Health Econ</source><year>2012</year>;<volume>13</volume>:<fpage>347</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">21442437</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaturvedi</surname><given-names>AK</given-names></name><name><surname>Engels</surname><given-names>EA</given-names></name><name><surname>Gilbert</surname><given-names>ES</given-names></name><etal></etal></person-group><article-title>Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk</article-title>. <source>J Natl Cancer Inst</source><year>2007</year>;<volume>99</volume>:<fpage>1634</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">17971527</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Vaittinen</surname><given-names>P</given-names></name></person-group><article-title>Second primary cancer after in situ and invasive cervical cancer</article-title>. <source>Epidemiology</source><year>2000</year>;<volume>11</volume>:<fpage>457</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">10874555</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>CJ</given-names></name><name><surname>Huon</surname><given-names>LK</given-names></name><name><surname>Hu</surname><given-names>YW</given-names></name><etal></etal></person-group><article-title>Secondary primary malignancy risk in patients with cervical cancer in Taiwan: a nationwide population-based study</article-title>. <source>Medicine (Baltimore)</source><year>2015</year>;<volume>94</volume>:<fpage>e1803</fpage>.<pub-id pub-id-type="pmid">26512575</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Second Primary Tumors.</article-title><source>Encyclopedia of Cancer</source><edition>3rd ed</edition><publisher-loc>Berlin, Heidelberg</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>2012</year><fpage>2676</fpage>.</mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HW</given-names></name><name><surname>Tu</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><etal></etal></person-group><article-title>Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study</article-title>. <source>Lancet Oncol</source><year>2011</year>;<volume>12</volume>:<fpage>900</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">21835693</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HF</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name></person-group><article-title>Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications</article-title>. <source>Hepatology</source><year>2010</year>;<volume>52</volume>:<fpage>155</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">20578004</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Te</surname><given-names>VC</given-names></name><name><surname>Randimbison</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Second primary cancers after in situ and invasive cervical cancer</article-title>. <source>Epidemiology</source><year>2001</year>;<volume>12</volume>:<fpage>281</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">11246596</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinerman</surname><given-names>RA</given-names></name><name><surname>Boice</surname><given-names>JD</given-names><suffix>Jr</suffix></name><name><surname>Storm</surname><given-names>HH</given-names></name><etal></etal></person-group><article-title>Second primary cancer after treatment for cervical cancer. An international cancer registries study</article-title>. <source>Cancer</source><year>1995</year>;<volume>76</volume>:<fpage>442</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="pmid">8625126</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purdie</surname><given-names>DM</given-names></name><name><surname>Bain</surname><given-names>CJ</given-names></name><name><surname>Siskind</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Ovulation and risk of epithelial ovarian cancer</article-title>. <source>Int J Cancer</source><year>2003</year>;<volume>104</volume>:<fpage>228</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">12569579</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiaffarino</surname><given-names>F</given-names></name><name><surname>Pelucchi</surname><given-names>C</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Breastfeeding and the risk of epithelial ovarian cancer in an Italian population</article-title>. <source>Gynecol Oncol</source><year>2005</year>;<volume>98</volume>:<fpage>304</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">15975644</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risch</surname><given-names>HA</given-names></name><name><surname>Howe</surname><given-names>GR</given-names></name></person-group><article-title>Pelvic inflammatory disease and the risk of epithelial ovarian cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prevent</source><year>1995</year>;<volume>4</volume>:<fpage>447</fpage>–<lpage>51</lpage>.</mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parazzini</surname><given-names>F</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Pelvic inflammatory disease and risk of ovarian cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prevent</source><year>1996</year>;<volume>5</volume>:<fpage>667</fpage>–<lpage>9</lpage>.</mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Hertzen</surname><given-names>LC</given-names></name><name><surname>Joensuu</surname><given-names>H</given-names></name><name><surname>Haahtela</surname><given-names>T</given-names></name></person-group><article-title>Microbial deprivation, inflammation and cancer</article-title>. <source>Cancer Metastasis Rev</source><year>2011</year>;<volume>30</volume>:<fpage>211</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">21253828</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinchant</surname><given-names>M</given-names></name><name><surname>Poncelet</surname><given-names>C</given-names></name><name><surname>Ziol</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Malignant transformation of abdominal wall endometriosis: case report and literature review</article-title>. <source>Tumori</source><year>2013</year>;<volume>99</volume>:<fpage>e49</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">23748829</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manavi</surname><given-names>K</given-names></name></person-group><article-title>A review on infection with Chlamydia trachomatis</article-title>. <source>Best Pract Res Clin Obstet Gynaecol</source><year>2006</year>;<volume>20</volume>:<fpage>941</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">16934531</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokajuk</surname><given-names>A</given-names></name><name><surname>Krzyzanowska-Grycel</surname><given-names>E</given-names></name><name><surname>Tokajuk</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Antidiabetic drugs and risk of cancer</article-title>. <source>Pharmacol Rep</source><year>2015</year>;<volume>67</volume>:<fpage>1240</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">26481548</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannucci</surname><given-names>E</given-names></name><name><surname>Harlan</surname><given-names>DM</given-names></name><name><surname>Archer</surname><given-names>MC</given-names></name><etal></etal></person-group><article-title>Diabetes and cancer: a consensus report</article-title>. <source>Diabetes Care</source><year>2010</year>;<volume>33</volume>:<fpage>1674</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="pmid">20587728</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>EJ</given-names></name><name><surname>LeRoith</surname><given-names>D</given-names></name></person-group><article-title>Obesity and diabetes: the increased risk of cancer and cancer-related mortality</article-title>. <source>Physiol Rev</source><year>2015</year>;<volume>95</volume>:<fpage>727</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">26084689</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Entman</surname><given-names>SS</given-names></name><name><surname>Salyer</surname><given-names>SL</given-names></name><etal></etal></person-group><article-title>Increased risk of endometritis and wound infection after cesarean section in insulin-dependent diabetic women</article-title>. <source>Am J Obstet Gynecol</source><year>1986</year>;<volume>155</volume>:<fpage>297</fpage>–<lpage>300</lpage>.<pub-id pub-id-type="pmid">3740145</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Forte</surname><given-names>V</given-names></name><name><surname>Abdallah</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Diabetes mellitus and the risk of cancer</article-title>. <source>Minerva Endocrinol</source><year>2011</year>;<volume>36</volume>:<fpage>187</fpage>–<lpage>209</lpage>.<pub-id pub-id-type="pmid">22019750</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>A</given-names></name><name><surname>Rositch</surname><given-names>A</given-names></name><name><surname>Qeadan</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Age-specific prevalence of HPV16/18 genotypes in cervical cancer: a systematic review and meta-analysis</article-title>. <source>Int J Cancer</source><year>2016</year>;<volume>138</volume>:<fpage>2795</fpage>–<lpage>803</lpage>.<pub-id pub-id-type="pmid">26661889</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>SK</given-names></name><name><surname>Ngan</surname><given-names>HY</given-names></name><name><surname>Chu</surname><given-names>TY</given-names></name><etal></etal></person-group><article-title>Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan</article-title>. <source>Vaccine</source><year>2008</year>;<volume>26</volume><issue>suppl 12</issue>:<fpage>M60</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">18945415</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty Alexander</surname><given-names>LE</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name></person-group><article-title>Inflammatory diseases of the lung induced by conventional cigarette smoke: a review</article-title>. <source>Chest</source><year>2015</year>;<volume>148</volume>:<fpage>1307</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">26135024</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004198 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 004198 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:5134872
|texte= Pelvic inflammatory disease increases the risk of a second primary malignancy in patients with cervical cancer treated by surgery alone
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:27893679" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |